OBIO® and TIAP Invest in A4i to Advance AI Analytics for Mental Health Risk Detection

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

OBIO® and Toronto Innovation Acceleration Partners (TIAP) invested $100,000 CAD in non-dilutive funding in A4i (App4Independence), an innovative digital platform supporting individuals with complex behavioural health needs. This funding, part of OBIO’s Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence “De-Risking of Emerging Technologies and Venture Creation” funding stream, will accelerate A4i’s development of AI-powered analytics tools designed to detect early signs of relapse, augment peer-support and reduce hospital readmission rates among patients with severe mental illness.

A4i is an alumnus of our EAHN™ program.

Arsheen Kaur
Previous

Afynia Laboratories Closes $5M Seed Round, Proceeds to Help Revolutionize Endometriosis Care
Next

FACIT and OBIO® announce inaugural WeSEED cohort of women-led start-ups in joint seed capital and commercialization program